Literature DB >> 12721863

[Bilateral subthalamic nucleus deep-brain stimulation (STN-DBS) in Parkinson's disease: initial experience in Cruces Hospital].

E Lezcano1, J C Gómez, I Lambarri, G Bilbao, I Pomposo, O Rodríguez, R Villoria, J J Zarranz, P Madoz, J Garibi.   

Abstract

INTRODUCTION: Clinical outcomes of Parkinson's disease patients treated for 12 months with STN-DBS were analyzed. PATIENTS ADN
METHODS: Twelve patients were selected using the CAPSIT protocol criteria and placement of electrodes in the appropriate target was performed according to results of fusion image techniques and intraoperative microrecording.
RESULTS: A reduction in motor UPDRS (44 %) and activities of daily living (58 %) scores during <<off>> phases were observed. <<On>> time with dyskinesias was reduced (86 %), while severe dyskinesias disappeared. Levodopa dosage was also lowered (44 %). Patients and caregivers showed a clear-cut benefit on quality of life (58 % and 61 % respectively). No cognitive deterioration was observed and morbidity was in the same range as that published by other teams.
CONCLUSION: Bilateral STN-DBS is an effective symptomatic therapy for complicated Parkinsońs disease patients. It improves the quality of life of patients and their caregivers and allows a reduction of levodopa dosage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721863

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  2 in total

1.  Long-term impact on quality of life of subthalamic nucleus stimulation in Parkinson's disease.

Authors:  Elena Lezcano; Juan Carlos Gómez-Esteban; Beatriz Tijero; Gaizka Bilbao; Imanol Lambarri; Olivia Rodriguez; Rafael Villoria; Ainara Dolado; Koldo Berganzo; Ana Molano; Edurne Ruiz de Gopegui; Iñigo Pomposo; Iñigo Gabilondo; Juan José Zarranz
Journal:  J Neurol       Date:  2016-03-10       Impact factor: 4.849

Review 2.  The effect of deep brain stimulation on quality of life in movement disorders.

Authors:  A Diamond; J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.